Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YRA-1909 in RA patients with inadequate response to MTX
NCT03275025Phase 2Completed
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YRA-1909 in rheumatoid arthritis (RA) (4 arms), sponsored by Yungjin Pharm. Co., Ltd. Primary endpoints: American College of Rheumatology 20 Response Rate at 12 weeks and Percentage of Participants With Adverse Events at 12 weeks. Started Apr 2017; status: completed.
02
Drugs
YRA-1909
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03275025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275025.